To refer to this page use:
|Abstract:||The p53 protein ensures cellular fidelity by suppressing or killing cells under stresses that enhance the mutation rate. Evidence suggests that the p53 protein may also ensure the fidelity of the epigenome. In this study a group of drugs that alter the deoxycytosine methylation patterns in cellular DNA are shown to preferentially kill human and mouse cells that contain p53 mutations or deficiencies. These observations are extended to mice that contain p53 deficiencies or missense mutations in their genome, which are preferentially killed when compared to mice with a wild type p53 gene. This is also the case for human cancer cell xenografts containing p53 mutations, which preferentially are killed by these drugs when compared to similar tumors with wild type p53. The loss of p53 function enhances a synthetic lethality with drugs that block or alter the patterns of deoxycytidine methylation in the genome.|
|Citation:||Yi, Lan, Sun, Yvonne, Levine, Arnold J. (2014). Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget, 5 (19), 8924 - 8936. doi:10.18632/oncotarget.2441|
|Pages:||8924 - 8936|
|Type of Material:||Journal Article|
|Version:||Final published version. This is an open access article.|
Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.